Child know-how firm Owlet introduced it’s increasing its attain inside Europe by extending entry to its child monitor Dream Sock in Greece, Poland, the Czech Republic, Romania, Slovakia, Hungary and Bulgaria.
Dream Sock, which obtained FDA clearance final November and CE Mark certification in Might, wraps round a child’s foot and gathers reside well being readings of infants 0-18 months who weigh 6-30 kilos.
The machine screens the toddler’s coronary heart price, oxygen saturation and sleep state, and in addition gathers waking information. Dad and mom additionally obtain well being notifications by way of the corporate’s app.
“Dream Sock has already made a huge effect on 1000’s of households since its world launch a couple of months in the past, and we’re desirous to proceed the roll-out of our medical-grade know-how to much more dad and mom,” Kurt Workman, Owlet CEO and cofounder, stated in an announcement.
THE LARGER TREND
Owlet went public via a SPAC in 2021. Its inventory is presently buying and selling round $4.52 per share on the NYSE, down from a excessive of $150.78 in 2021.
Final 12 months, the corporate raised $30 million in non-public placement financing, and, in February of this 12 months, it raised one other $9 million.
In August, the corporate reported its second quarter 2024 monetary outcomes, noting income of $20.7 million, up 58% year-over-year from roughly $13.1 million.
Working bills have been $12.5 million in Q2, in comparison with $11.9 million for a similar interval final 12 months, and working loss was $2.2 million, in comparison with $6.7 million within the second quarter of 2023.
The Utah-based firm reported a web lack of $1.1 million for the second quarter in comparison with a lack of $8.5 million for Q2 2023.
Its adjusted EBITDA was $0.1 million in Q2 2024 in comparison with a lack of $4.3 million for a similar interval final 12 months.
The corporate expects its full-year 2024 web income to vary from $72.5 million to $77.5 million with adjusted EBITDA lack of $6 million to $3 million.
